Member Info for andyrp

Feel like a lone voice here! Positive RNS but share price drops, go figure???

Thanks Jimb2. Guess you’d had a drink before posting so I’ll forgive you.

sp please stay low until 28th November when I get my annual bonus and can buy more shares! Selfish I know but real returns are some months away anyway.

Thanks, that’s nothing new and just fundamentals, but that said, we are all aligned and no matter what we all have the same interest and want a return on our investment in Yu. Good luck to you (and also me!).

If you had the link you’d share it. If you are invested you’d want to create interest and more buys as that would drive the share price. Searching Twitter isn’t rocket science, it’s not high level company researc!

Share the links that show Twitter is “going mad about this” please. Personally I can’t see anything of the sort.

I got in below 156 was looking at 40% profit at the peak of the bounce and held on. I'm fairly new to this game so lesson learnt; should have taken something out and banked it. Will hold on now and see what happens. Just don't tell the wife!!!!!!!!

SP is falling for no apparent reason; is that the MMs trying to entice people to buy in and create a bit of interest in the share?

Iclaprim is intended to work against gram positive bacteria whist Omdacycline is a broad spectrum antibiotic intended to work against both gram postive and gram negative bacteria. Gram positive bacterial cells have a “thicker” cell wall whist the cell wall in gram negative bacteria is “thinner” and more porous. This difference means the antibiotic drug has to work differently to disrupt the functioning of the cell. “Gram” refers to the gram stain test used to differentiate between the different types of bacterial cell, in gram positive bacterial cellls the stain is held within the cell wall given the cell a purple colour under a microscope. In gram negative cells ( the ones with a porous cell wall) the stain passes through the cell wall.

It’s “no outstanding debt”; doesn’t mean there is no debt. Also they could sell the debt to a recovery firm who can then recover the debt providing the debtor is still trading and has assets etc. There’s plenty of good news in this share. Personally I bought in to benefit from the bounce but then decided to hold out for a longer term recovery in sp.

That’s how the market makers make their money, selling higher than they buy the shares for. A wide spread indicates some volatility and protects the market makers to some extent from sudden swings in the share price.

Definitely hitting and bouncing off the 150 to 155 mark.

Don’t think it will matter, they would have done their due diligence and would understand existing contracts. Might be change of ownership clauses in the contract but why would either party exercise them; they both stand to lose.

The RNS does indeed contain good news albeit with a long lead time for the MA applications. Interestingly the sp fell very quickly in response to the previous RNS (which is when I bought in hoping for a bounce) whilst a positive RNS does not have the opposite effect of triggering a rapid rise in sp.

I had bought in to DNL on the back of the sp falling albeit without doing a lot of research but now having looked at their product development pipeline and done my research I'm going to keep hold of my shares; in my opinion the sp will increase as product development progresses towards MA applications and product launches or because DNL have potential for a takeover by a bigger pharma company.

Anyway in all cases do you own research!

Isn’t the production licence key to the sp rocketing? The licence could take a couple of years to obtain unless somehow fast tracked - is that right?

Oh and first post and know know there is no edit function to correct the typos!

I bought this on the back of the sp crashing following the RNS that the clinical trial objective had nit been met; I also picked out the positives from the clinical trial results which convinced me to invest. However, given that the share price has crashed I wonder if big pharma are eyeing up DNL as a takeover target. DNL Havel got commercialised licensed medicinal products not yet launched in all markets, so plenty of growth opportunities, plus a few products in the development pipeline. Big pharma could easily integrate DNL and deliver some cost saving synergies and prop up weak pipelines resulting from cuts to R&D budgets.

I was hoping the sp would show a quick recovery of 10p and was going to sell for a quick profit. Obvious it we didn’t see the bounce I was hoping for so now going to stay invested for a little longer and watching this with interest.